Profile data is unavailable for this security.
About the company
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company’s Rx Segment consists of prescription pharmaceutical products sold primarily through third party wholesalers. The Rx Segment primarily consists of two product portfolios: attention deficit hyperactivity disorder (ADHD) Portfolio and Pediatric Portfolio. The Company's prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of ADHD, Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency.
- Revenue in USD (TTM)93.76m
- Net income in USD-13.68m
- Incorporated2015
- Employees150.00
- LocationAytu Biopharma Inc7900 E. Union Avenue, Suite 920DENVER 80237United StatesUSA
- Phone+1 (720) 437-6580
- Fax+1 (302) 636-5454
- Websitehttps://aytubio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioquest Corp | 0.00 | -507.41k | 8.61m | -- | -- | -- | -- | -- | -0.0485 | -0.0485 | 0.00 | -0.0467 | 0.00 | -- | -- | -- | -3,483.76 | -- | -- | -- | -- | -- | -- | -- | -- | -3.88 | -- | -- | -- | -- | 64.67 | -- | -- | -- |
| Lotus Pharmaceuticals Inc | 70.79m | 1.72m | 10.24m | 233.00 | 0.0687 | 0.0011 | 2.65 | 0.1446 | 0.0553 | 0.0553 | 2.56 | 3.58 | 0.6321 | 37.27 | 17.85 | 303,836.90 | 1.55 | 22.84 | 1.71 | 26.40 | 35.10 | 41.62 | 2.45 | 19.93 | 0.4428 | 30.80 | 0.0516 | 0.00 | 28.71 | 31.70 | -12.22 | 51.11 | 70.48 | -- |
| Healthy Extracts Inc | 2.88m | -1.37m | 11.26m | -- | -- | 28.14 | -- | 3.91 | -0.4725 | -0.4725 | 0.9845 | 0.1336 | 1.12 | 0.6654 | 28.03 | -- | -53.40 | -53.78 | -168.81 | -146.65 | 67.83 | 45.68 | -47.73 | -87.53 | 0.2059 | -0.9153 | 0.7131 | -- | 10.41 | 105.93 | -151.54 | -- | -- | -- |
| NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 11.84m | 1.00 | -- | 0.0661 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
| Aptorum Group Ltd | 431.38k | -2.82m | 12.15m | 3.00 | -- | 0.463 | -- | 28.16 | -0.9126 | -0.9126 | 0.0954 | 4.80 | 0.0208 | 30.36 | 3.88 | 143,793.30 | -20.92 | -40.45 | -19.62 | -42.36 | 2.45 | -4.04 | -1,006.30 | -1,233.68 | 1.18 | -- | 0.1694 | -- | -66.71 | 2.38 | 71.18 | -- | -78.15 | -- |
| Guardion Health Sciences Inc | 6.43m | -5.93m | 13.45m | 9.00 | -- | 0.9778 | -- | 2.09 | -4.61 | 4.97 | 5.04 | 10.71 | 0.4467 | 2.74 | 8.20 | 714,121.10 | -41.22 | -77.90 | -45.86 | -86.55 | 44.86 | 42.45 | -92.26 | -176.93 | 16.59 | -2.98 | 0.00 | -- | 10.85 | 67.03 | 101.00 | -- | -58.56 | -- |
| Aytu Biopharma Inc | 93.76m | -13.68m | 14.75m | 150.00 | -- | 0.4469 | -- | 0.1573 | -2.65 | -2.65 | 18.21 | 5.53 | 0.6792 | 2.42 | 2.93 | 625,053.30 | -9.91 | -33.56 | -25.58 | -52.81 | 65.32 | 56.89 | -14.60 | -73.81 | 0.6923 | 0.216 | 0.352 | -- | 11.10 | 96.56 | 84.33 | -- | -- | -- |
| Pharmacyte Biotech Inc | 0.00 | -17.24m | 14.82m | 2.00 | -- | 0.5611 | -- | -- | -1.93 | -1.93 | 0.00 | 4.92 | 0.00 | -- | -- | 0.00 | 0.5012 | -7.42 | 0.5333 | -7.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -299.38 | -- | -- | -- |
| Talphera Inc | 398.00k | -13.70m | 15.29m | 15.00 | -- | 1.20 | -- | 38.43 | -0.6353 | -0.6323 | 0.0185 | 0.7491 | 0.0187 | -- | -- | 26,533.33 | -64.37 | -22.60 | -78.11 | -28.55 | -- | -- | -3,443.22 | -714.87 | -- | -- | 0.00 | -- | -- | -21.26 | -119.16 | -- | -34.33 | -- |
| Cara Therapeutics Inc | 11.00m | -111.08m | 15.69m | 55.00 | -- | 1.35 | -- | 1.43 | -2.04 | -2.04 | 0.2017 | 0.2115 | 0.1063 | 1.10 | 2.10 | 199,927.30 | -107.38 | -35.76 | -132.61 | -40.82 | 74.66 | -- | -1,010.20 | -162.10 | 4.48 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| DH Enchantment Inc | 100.00 | -173.19k | 16.09m | 1.00 | -- | -- | -- | 160,915.00 | -0.0002 | -0.0002 | 0.00 | -0.0012 | 0.0438 | 0.1493 | -- | 100.00 | -7,579.43 | -- | -- | -- | 0.00 | -- | -173,190.00 | -- | 0.0029 | -14.85 | -- | -- | -95.43 | -- | 59.53 | -- | -- | -- |
| Nexgel Inc | 5.01m | -3.39m | 17.19m | 19.00 | -- | 3.85 | -- | 3.43 | -0.5722 | -0.5722 | 0.8464 | 0.6589 | 0.4942 | 3.03 | 6.44 | 263,631.60 | -35.74 | -44.61 | -48.15 | -56.19 | 23.74 | 5.02 | -72.33 | -180.98 | 0.8135 | -- | 0.1992 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
| Cumberland Pharmaceuticals, Inc. | 37.79m | -10.38m | 17.62m | 91.00 | -- | 0.6681 | -- | 0.4663 | -0.7328 | -0.7328 | 2.67 | 1.87 | 0.4501 | 0.8643 | 3.17 | 415,225.80 | -12.35 | -7.03 | -17.75 | -9.52 | 82.58 | 79.95 | -27.45 | -17.64 | 1.26 | -38.85 | 0.382 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
| Cyclo Therapeutics Inc | 1.13m | -20.74m | 18.68m | 8.00 | -- | -- | -- | 16.50 | -0.9104 | -0.9104 | 0.0474 | -0.1785 | 0.242 | 0.4002 | 13.16 | 141,553.80 | -443.08 | -132.22 | -- | -215.17 | 91.56 | 90.37 | -1,831.29 | -1,114.04 | 0.4283 | -- | -- | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
| TherapeuticsMD Inc | 996.00k | -4.83m | 19.14m | 1.00 | -- | 0.6918 | -- | 19.22 | -0.4348 | -0.5538 | 0.0889 | 2.40 | 0.0212 | -- | 0.5048 | 996,000.00 | -10.31 | -53.35 | -13.13 | -111.61 | 45.08 | 86.67 | -485.34 | -236.57 | -- | -- | 0.00 | -- | -98.14 | -39.53 | -816.85 | -- | -- | -- |
Data as of Sep 19 2024. Currency figures normalised to Aytu Biopharma Inc's reporting currency: US Dollar USD
34.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nantahala Capital Management LLCas of 30 Jun 2024 | 1.09m | 18.20% |
| Stonepine Capital Management LLCas of 30 Jun 2024 | 472.47k | 7.91% |
| Armistice Capital LLCas of 30 Jun 2024 | 252.00k | 4.22% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 74.12k | 1.24% |
| Geode Capital Management LLCas of 30 Jun 2024 | 35.92k | 0.60% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 27.89k | 0.47% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 22.79k | 0.38% |
| Dimensional Fund Advisors LPas of 30 Jun 2024 | 22.22k | 0.37% |
| Citadel Securities LLCas of 30 Jun 2024 | 21.81k | 0.37% |
| Acadian Asset Management LLCas of 30 Jun 2024 | 14.62k | 0.25% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
